Boston Scientific (NYSE:BSX) EVP Arthur Butcher Sells 17,313 Shares

Boston Scientific Corporation (NYSE:BSX) EVP Arthur Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Boston Scientific Stock Down 2.0%

Shares of NYSE BSX opened at $99.03 on Wednesday. The stock has a market cap of $146.80 billion, a PE ratio of 52.96, a price-to-earnings-growth ratio of 2.03 and a beta of 0.67. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The business has a 50-day moving average price of $99.28 and a 200 day moving average price of $102.19.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the previous year, the company posted $0.63 earnings per share. The firm’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in BSX. Riverwater Partners LLC increased its position in Boston Scientific by 3.3% during the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock worth $333,000 after purchasing an additional 98 shares during the period. Gerber Kawasaki Wealth & Investment Management boosted its stake in shares of Boston Scientific by 3.8% in the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after buying an additional 99 shares in the last quarter. Crown Wealth Group LLC grew its holdings in Boston Scientific by 4.7% during the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after acquiring an additional 100 shares during the period. IVC Wealth Advisors LLC raised its position in Boston Scientific by 4.9% in the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock worth $236,000 after acquiring an additional 102 shares in the last quarter. Finally, Claret Asset Management Corp raised its position in Boston Scientific by 4.4% in the third quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after acquiring an additional 102 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 11th. Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and upped their target price for the company from $118.00 to $125.00 in a report on Monday, September 8th. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a research note on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.